INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Price, Quote, News and Overview
NASDAQ:NVIV - Nasdaq - US46186M6057 - Common Stock - Currency: USD
NVIV Quote, Performance and Key Statistics
0.3207
-0.17 (-34.28%)
The current stock price of NVIV is 0.3207 USD. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.
NVIV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.28 | 234.48B | ||
| ISRG | INTUITIVE SURGICAL INC | 72.93 | 199.70B | ||
| BSX | BOSTON SCIENTIFIC CORP | 39.46 | 157.58B | ||
| SYK | STRYKER CORP | 31.09 | 148.69B | ||
| MDT | MEDTRONIC PLC | 16.17 | 110.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.54 | 50.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.93 | 45.76B | ||
| IDXX | IDEXX LABORATORIES INC | 45.36 | 41.91B | ||
| RMD | RESMED INC | 27.33 | 36.38B | ||
| DXCM | DEXCOM INC | 52.93 | 34.25B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.62 | 32.90B | ||
| STE | STERIS PLC | 26.82 | 24.61B |
Related stock screener links
About NVIV
Company Profile
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
Company Info
INVIVO THERAPEUTICS HOLDINGS
Building 1400 East 4Th Floor, One Kendall Square
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Toselli
Employees: 6
Phone: 16178635524
INVIVO THERAPEUTICS HOLDINGS / NVIV FAQ
What is the stock price of INVIVO THERAPEUTICS HOLDINGS today?
The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.
What is the ticker symbol for INVIVO THERAPEUTICS HOLDINGS stock?
The exchange symbol of INVIVO THERAPEUTICS HOLDINGS is NVIV and it is listed on the Nasdaq exchange.
On which exchange is NVIV stock listed?
NVIV stock is listed on the Nasdaq exchange.
What is INVIVO THERAPEUTICS HOLDINGS worth?
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.
How many employees does INVIVO THERAPEUTICS HOLDINGS have?
INVIVO THERAPEUTICS HOLDINGS (NVIV) currently has 6 employees.
What are the support and resistance levels for INVIVO THERAPEUTICS HOLDINGS (NVIV) stock?
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a resistance level at 0.63. Check the full technical report for a detailed analysis of NVIV support and resistance levels.
Should I buy INVIVO THERAPEUTICS HOLDINGS (NVIV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVIV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVIV, evaluating the profitability, health, valuation and growth aspects
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Sales and EPS estimates to see what analysts future expectations are.
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Insider and Institutional Ownership to learn about the owners and their transactions.
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Chart to make your own analysis
- INVIVO THERAPEUTICS HOLDINGS (NVIV) Latest news and press-releases to stay up to date.
Does INVIVO THERAPEUTICS HOLDINGS (NVIV) stock pay dividends?
NVIV does not pay a dividend.
What is the Price/Earnings (PE) ratio of INVIVO THERAPEUTICS HOLDINGS (NVIV)?
INVIVO THERAPEUTICS HOLDINGS (NVIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).
NVIV Technical Analysis
NVIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVIV. While NVIV has a great health rating, there are worries on its profitability.
NVIV Financial Highlights
Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -104.6% | ||
| Debt/Equity | 0 |
NVIV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to NVIV. The Buy consensus is the average rating of analysts ratings from 7 analysts.